Rimonabant
CB1 antagonist / Rimonabant is a selective CB1 receptor inverse agonist (Ki = 1.8 nM).1,2 It is an anorectic antiobesity drug originally approved for use in Europe but eventually withdrawn from the market because of potential severe psychiatric side effects.
Biochemicals & reagents
168273-06-1
Acomplia; SR141716
1) Rinaldi-Carmona et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS.Lett. 350 240. / 2) Rinaldi-Carmona et al. (1995) Biochemical and pharmacological characterization of SR141716A, the first potent and selective cannabinoid receptor antagonist Life Sci. 56 1941
RT
TARGET: GPCR -- PATHWAY: Fatty acid metabolism; Cholesterol metabolism; Carbohydrate metabolism -- DISEASE AREA: Obesity